Profound Medical Corp. Common Stock (PROF)

About PROF

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate…

Sector

Health Care

Industry

Medical/Dental Instruments

Employees

162

Website

profoundmedical.com/

Fundamentals

1-day range

$6.83$6.94

Market cap

$299.42M

P/E (trailing)

—

P/E (forward)

-11.65

EPS (trailing)

$-1.25

Dividend yield

—

Beta

1.94

Avg. volume

96.2K

Dividend pay date

October 16, 2019

Forecasts

5 analyst ratings

Profound Medical Corp. Common Stock Competitors

Chosen by industry and closest market cap.

• PROF

  Profound Medical Corp. Common Stock

  $6.86

  ▼ 1.44%
  Market cap $299.42MP/E —
  $5.23$12.4
• TMCI

  Treace Medical Concepts Inc. Common Stock

  $4.67

  ▲ 1.41%
  Market cap $303.61MP/E —
  $1.17$7.63
• MOBI

  Mobia Medical Inc. Common Stock

  $11.37

  ▲ 7.22%
  Market cap $377.38MP/E —
  $10.19$15.29
• PDEX

  Pro-Dex Inc. Common Stock

  $62.37

  ▼ 3.85%
  Market cap $203.09MP/E 17.93
  $23.47$69.86
• LUCD

  Lucid Diagnostics Inc. Common Stock

  $0.9989

  ▲ 1.51%
  Market cap $196.65MP/E —
  $0.8605$1.63
• APYX

  Apyx Medical Corporation Common Stock

  $3.08

  ▲ 2.67%
  Market cap $175.19MP/E —
  $1.7$5.08
• NPCE

  Neuropace Inc. Common Stock

  $14.41

  ▲ 1.98%
  Market cap $460.27MP/E —
  $8.76$19.6

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Profound Medical Corp. (PRN:CA) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/7/2026
• Profound Medical Affirms FY2026 Sales Guidance of $25.000M vs $26.858M Est
  benzinga · 8/6/2026
• Profound Medical Affirms FY2026 Sales Guidance of $25.000M vs $26.858M Est
  Benzinga · 8/6/2026
• Profound Medical Q2 EPS $(0.26), Inline, Sales $2.483M Miss $5.500M Estimate
  Benzinga · 8/6/2026

Institutional Ownership

March 31, 2026

Total shares held

16.43M

Total value held

$102.78M

Institutional holders

58